TickerTalks
Browse all tickers →
TickerTalks›$GUTS
GUGUTS

Fractyl Health, Inc.

$GUTS·$51M·Biotechnology·Healthcare
$0.66-11.2%YTD-68.9%1Y-33.4%
Mentions · last 7 days
2026-08-20: 1 posts2026-08-21: 2 posts2026-08-22: 0 posts2026-08-23: 1 posts9-11%
Price updated 2d ago·X counts updated 7d ago
GUGUTS
$GUTSFractyl Health, Inc.
$0.66-11.16%9 posts-11%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $GUTS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-08-29

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Metabolic-device biotech with positive REMAIN-1 data + Wainwright PT $8; class-action + $0.66 price captures the debated risk-reward.

Fractyl Health is a $50M metabolic-therapeutics clinical-stage biotech (Revita DMR duodenal metabolic therapy device for T2D + obesity, plus gene-therapy pipeline) at $0.659 — -69% YTD, -33% t12m, sitting at just 13.7% of its 52w range and -33% below the 200d.

  • Q2 EPS -$0.12 vs -$0.14 (+11% beat), Q1 $0.06 vs -$0.17 (+135% beat — brief positivity), Q4 2025 -$0.29 vs -$0.19 (-53% miss). Volatile cadence.
  • Revenue zero (all reported quarters); cash burn ~$22M/quarter.
  • Cash economics: PE -0.48, PS 0, ROIC -104%, D/E 2.84 (elevated leverage), FCF yield -179% (extreme burn), EV/EBITDA -0.51.
  • Analyst path FY26 EPS -$0.35 → FY27 -$0.47 — Street models modest continued burn.
  • MAJOR CATALYST: REMAIN-1 Midpoint Cohort study one-year data (July 15 disclosure) — durable weight maintenance one year after GLP-1 discontinuation with Revita. This is the key data validating Revita.
  • Multiple securities-class-action lawsuits (Robbins, Bronstein, Levi & Korsinsky) with Oct 20 lead-plaintiff deadline — legal overhang despite the positive REMAIN-1 data.
  • Sentiment (7 posts): bullish — REMAIN-1 midpoint cohort data positive, H.C. Wainwright reiterates Buy PT $8, Morgan Stanley PT $2, pivotal cohort data expected early Q4, potential De Novo FDA submission late Q4, approval seen ~80% derisked.

Read as a metabolic-device biotech with durable positive REMAIN-1 midpoint data supporting the GLP-1-post-discontinuation weight-maintenance thesis, but facing real class-action + dilution risk at $0.66; the debated question is whether pivotal Q4 cohort data + FDA submission delivers the rerate or the litigation/dilution compounds first.

Agrees with X sentimentX is bullish on REMAIN-1 data + FDA-derisked timeline; verdict aligns while flagging the litigation and dilution risk.

What to watch: Q4 pivotal cohort data, De Novo FDA submission timing, Oct 20 class-action deadline, and any raise announcements.

On the calendar: 2026-11-11 Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-07-22

Fractyl Health reports positive REMAIN-1 midpoint cohort data showing durable weight maintenance one year after GLP-1 discontinuation. H.C. Wainwright reiterates Buy PT $8, Morgan Stanley PT $2, with pivotal cohort data expected early Q4 and potential De Novo FDA submission late Q4. Approval seen ~80% derisked.

Read the AI verdict + X sentiment for $GUTS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops the Revita duodenal mucosal resurfacing procedure targeting type 2 diabetes and obesity without systemic drugs.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $GUTS.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $GUTS

Neutral — Develops the Revita duodenal mucosal resurfacing procedure targeting type 2 diabetes and obesity without systemic drugs; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-0.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-104%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-179%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-45.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
2.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 10, 2026$-0.12$-0.14+11.1%
Q1 2026May 12, 2026$0.06$-0.17+135.3%
Q4 2025Mar 24, 2026$-0.29$-0.19-52.6%
Q3 2025Nov 12, 2025$-0.71$-0.34-108.8%
Next earningsWed, Nov 11·consensus EPS $-0.13

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$0.12$-22.5M
Q4 FY25$0-100.0%——$-0.58$-21.3M
Q3 FY25$0-100.0%——$-0.71$-22.7M
Q2 FY25$0-100.0%——$-0.57$-21.3M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$12.4M$5.7M – $31.9M-$0.35-$0.40 – -$0.314
FY27$17.9M$8.1M – $45.9M-$0.47-$0.69 – -$0.323
FY28$78.1M$16.5M – $284.0M-$0.31-$0.42 – -$0.185
FY29$252.5M$114.8M – $647.4M$0.09$0.03 – $0.282
FY30$461.4M$209.8M – $1.2B$0.62$0.18 – $1.882

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.14%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-12.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-32.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 129.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.325-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJun 12Ajay RoyanDirector23.0K sh$20KBuyJun 10Harith RajagopalanCEO25.0K sh$18KBuyJun 10William BradleyDirector68.5K sh$50KBuyJun 10Ian SheffieldDirector35.0K sh$26KBuyJun 8Smith Weber LaraCFO20.0K sh$14K
+ 8 other (8 awards) in window

See when $GUTS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJul 158-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Fractyl Health (GUTS) disclosed one-year data from the REMAIN-1 Midpoint Cohort study for its Revita duodenal metabolic therapy device on July 15, 2026. The blinded, sham-controlled study demonstrated dose-dependent durability of weight maintenance at one year following discontinuation of GLP-1 receptor agonist therapy. Data confirmed that the metabolic effect achieved with Revita persists after GLP-1 drugs are stopped, a key differentiator in the obesity/metabolic disease space. An investor webcast to present the data was held on July 15, 2026, at 8:00 a.m. Eastern Time.

8-KShareholder voteJun 118-K — Item 5.07: Shareholder vote
AI summary

Fractyl Health, Inc. (ticker GUTS) held its 2026 Annual Meeting on June 10, 2026, with ~70.7% of 158.6M eligible shares represented. Three Class II directors were elected for three-year terms: Marc Elia (65.2M For), Clive Meanwell (63.7M For), and Ian Sheffield (73.8M For, nearly unopposed); Ernst & Young LLP was ratified as independent auditor (107.9M For, 0.2M Against). All proposals passed. Routine governance with no contested items and modest opposition to the other two directors, consistent with normal institutional abstention patterns.

8-KPress release / Reg FDJun 48-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Fractyl Health, Inc. (GUTS) disclosed its addition to Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 under 8-K Item 8.01 (other events). Index inclusions are significant because they trigger automatic buying from passive index funds and ETFs that track the benchmark, often resulting in increased share price and trading volume. Index providers typically announce additions in advance of the effective rebalancing date, giving institutions time to adjust their holdings. The event increases GUTS's institutional ownership base and enhances its market visibility and liquidity profile.

8-KPress release / Reg FDMay 118-K — Item 7.01: Press release / Reg FD
AI summary

GUTS filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-05-11. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

8-KPress release / Reg FDMar 248-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

GUTS reported period ending 2026-03-24 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

8-KListing / delisting noticeMar 178-K — Item 3.01: Listing / delisting notice
+ 13 other (3 proxys · 3 13Gs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

GUTS Shareholder Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Fractyl Health, Inc. Securities Class Actionglobenewswire.com·2d agoBronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harmfeeds.newsfilecorp.com·2d agoBronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com·2d agoLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 20, 2026 in Fractyl Health, Inc. Lawsuit - GUTSgurufocus.com·2d agoLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 20, 2026 in Fractyl Health, Inc. Lawsuit - GUTSbusinesswire.com·2d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on XGLP-1 & Weight LossGene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport